RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $89 from $85 and keeps an Outperform rating on the shares. Edwards delivered sales and EPS upside and raised the low end of 2025 revenue guidance, noting confidence at the high end of EPS, the analyst tells investors in a research note. The current sentiment and valuation support upside, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $81 from $75 at Canaccord
- Edwards Lifesciences price target raised to $94 from $85 at Deutsche Bank
- Edwards Lifesciences price target raised to $85 from $80 at JPMorgan
- Edwards Lifesciences: Strong Financial Performance and Strategic Advancements Drive Buy Rating
- Edwards Lifesciences price target raised to $90 from $83 at Piper Sandler